INTRODUCTION

Histone deacetylase (HDAC) has been recognized as a potentially useful therapeutic target for cardiovascular disorders. However, the effect of the HDAC inhibitor, trichostatin A (TSA), on vasoreactivity and hypertension remains unknown. We performed aortic coarctation at the inter-renal level in rats in order to create a hypertensive rat model. Hypertension induced by abdominal aortic coarctation was significantly suppressed by chronic treatment with TSA (0.5 mg/kg/day for 7 days). Nicotinamide adenine dinucleotide phosphate-driven reactive oxygen species production was also reduced in the aortas of TSA-treated aortic coarctation rats. The vasoconstriction mediated by angiotensin II (Ang II, 100 nM) was inhibited by TSA in both endothelium-intact and endothelium-denuded rat aortas, suggesting that TSA has mainly activated vascular smooth muscle cells (VSMCs). In cultured rat aortic VSMCs, Ang II increased p66shc phosphorylation, which was inhibited by the Ang II receptor type 1 (AT1R) inhibitor, valsartan (10 μM), but not by the AT2R inhibitor, PD123319. TSA (1–10 μM) inhibited Ang II-induced p66shc phosphorylation in VSMCs and in HEK293T cells expressing AT1R. Taken together, these results suggest that TSA treatment inhibited vasoconstriction and hypertension via inhibition of Ang II-induced phosphorylation of p66shc through AT1R.

Key Words: Angiotensin II, Angiotensin receptor type I, Hypertension, p66shc, Trichostatin A
of HDAC inhibition on aortic coarctation-induced hypertension remains unclear.

Therefore, we investigated the effect of the HDAC inhibitor, trichostatin A (TSA), on blood pressure in aortic coarctation hypertensive rats and on Ang II-induced vasoconstriction and its underlying mechanisms in rat aortas and vascular smooth muscle cells (VSMCs).

METHODS

Reagents

TSA, valsartan, PD123319, and Ang II were obtained from Sigma-Aldrich (St. Louis, MO, USA). The following antibodies were used: phospho-ser36-p66shc (Calbiochem, La Jolla, CA, USA), Shc (BD Biosciences, Franklin Lakes, NJ, USA), and β-actin (Santa Cruz Biotechnology, CA, USA). Lipofectamine 2000 was purchased from Life Technologies (Carlsbad, CA, USA) and a chemiluminescence kit from Amersham Pharmacia Biotech (Piscataway, NJ, USA).

Cell culture

Rat VSMCs were isolated from Sprague Dawley rats [12]. The aorta was removed under sterile conditions and the adventitia was removed. The aorta was minced and digested in 5 mL digest solution (1 mg/mL collagenase, 0.1% bovine serum albumin) at 37°C for 30 min. Verification of VSMCs was confirmed by positive immunocytochemistry staining for α-smooth muscle cell actin using a commercial kit (Sigma-Aldrich). Human embryonic kidney 293 T cells were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were grown in Dulbecco-modified Eagle medium (DMEM, Life Technologies) with 10% fetal bovine serum, 10 U/mL penicillin, and 10 μg/mL streptomycin.

Transient transfection of angiotensin receptor subtypes

Plasmids containing AT1R cDNA (NM_04835) and AT2R cDNA (NM_000686) were purchased from Origene (Rockville, MD, USA). Human full-length AT1R cDNA and AT2R cDNA was subcloned into pCMV-Tag2A or pEGFP plasmids, which were verified via sequencing. HEK293T cells were transfected with AT1R or AT2R (1 μg/well) using lipofectamine 2000 according to the manufacturer’s protocol.

Animal studies

Male Sprague Dawley rats (5–6 week-old and weighing 200–250 g, n=20) were purchased from Samtako, Inc. (Osan, Korea) and housed in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the Chungnam National University. All animal experiments were approved by the IACUC. Rats were randomly assigned to the abdominal aortic coarctation and sham-operated control groups. In brief, after anesthesia via intraperitoneal injection of a mixture of ketamine (80 mg/kg) and xylazine (12 mg/kg), Polyethylene tubing (PE-50) was inserted into the left common carotid artery and femoral artery and connected to a pressure transducer (Gould P23XL) and preamplifier (Grass Model PI-1, USA). The systolic, diastolic, and mean blood pressures were analyzed with the Chartpro software (ADInstruments, Colorado Springs, CO, USA).

Measurement of vascular contractility

The aortas were cut into rings of 2–3 mm in length. Each ring was connected to an isometric force transducer (MultiMyograph 610M, Danish MyoTechnology, Denmark), suspended in an organ chamber filled with 7.5 mL of Krebs buffer solution (NaCl 100 mM, KCl 4.7 mM, CaCl2 1.9 mM, MgSO4 1.2 mM, KHPO4 1.03 mM, and NaHCO3 25 mM, pH 7.4) and aerated with a 95% O2/5% CO2 mixture at 37°C. The isometric tension was recorded continuously. A high K+ (60 mM) solution was prepared by replacing NaCl with equimolar KCl. These solutions were saturated with a 95% O2/5% CO2 mixture at 37°C and pH 7.4. Dose-response curves for Ang II treatment (1–100 nM) were obtained by cumulative Ang II application. Endothelial removal was confirmed by the absence of relaxation when acetylcholine (1 μM) was applied to aortic rings that contracted with 300 nM of phenylephrine. The contractions were expressed as a percentage of the pre-contracted tension obtained with a high K+ (60 mM) solution.

Detection of superoxide anion by lucigenin chemiluminescence

Dark-adapted lucigenin solution (5 μM) was prepared in aerated Krebs-HEPES buffer [15]. The aortic rings were immersed in the lucigenin solution and chemiluminescence was detected with a luminometer (Lumat, Bad Wildbad, Germany). The chemiluminescence signal was integrated over 2 min.

Western blotting

Forty micrograms of protein were separated on 7.5–10% SDS/PAGE gel and transferred onto polyvinylidene difluoride membranes. After blocking for 1 h in 5% skim milk solution, the membranes were incubated with specific antibodies to phospho-ser36-p66shc, Shc, and β-actin. Protein expression was detected using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech) and quantified densitometrically using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA).

Statistical analysis

All data are expressed as the mean±S.E.M. A statistical evaluation was performed using one-way ANOVA, followed by a Turkey post-hoc test. A p-value of p<0.05 was considered statistically significant.

RESULTS

Chronic treatment with TSA suppressed aortic coarctation-induced hypertension

We investigated the effect of TSA on blood pressure in
sham and aortic coarctation-induced hypertensive rats. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and pulse pressure (PP) were significantly higher in aortic coarctation-induced hypertensive rats. Chronic treatment with TSA (0.5 mg/kg/day) for 7 days significantly reduced high arterial blood pressure induced by aortic coarctation (Fig. 1A). As shown in Fig. 1A, chronic treatment with TSA significantly reduced SBP in aortic coarctation rats (169.8±8.2 mmHg vs. 133.1±5.5 mmHg, p<0.05), but did not reduce SBP in sham rats (125.5±3.0 mmHg vs. 112.9±9.5 mmHg). Additionally, even though DBP and MAP were reduced in TSA-treated sham and aortic coarctation-rats, the anti-hypertensive effect of TSA in aortic coarctation rats was greater than that in sham-operated rats.

**Chronic treatment with TSA inhibited aortic coarctation-induced superoxide production**

Next, we examined whether TSA attenuates aortic coarctation-induced superoxide production. Superoxide production was measured in basal conditions and in nicotinamide adenine dinucleotide phosphate (NADPH)-treated rat aorta using a lucigenin chemiluminescence assay. Basal and NADPH-driven superoxide production was much higher in rats with aortic contraction than in sham-operated rats. However, chronic treatment with TSA (0.5 mg/kg/day) for 7 days significantly reduced NADPH-driven superoxide production induced by aortic coarctation. TSA had no effect on NADPH-driven ROS production in sham-operated rats (Fig. 1B).

**TSA inhibited Ang II-induced vasoconstriction in isolated rat aortas**

We investigated whether TSA influences Ang II-induced vasoconstriction in rat aortas. Aortic rings were pretreated with TSA (1~10 μM) for 15 min. As shown in Fig. 2A, TSA pretreatment inhibited Ang II-induced vasoconstriction in endothelium-intact aortic rings. The inhibitory activity of TSA on Ang II-induced vasoconstriction showed a dose dependency. Interestingly, TSA also inhibited Ang II-induced vasoconstriction in endothelium-rubbed aortic rings (Fig. 2B). The inhibitory action of TSA in endothelium-rubbed aortic rings was much greater than that for the intact endothelium, suggesting that TSA has mainly acted in VSMCs.

**AT,R was involved in p66shc phosphorylation**

Activation of p66shc modulates the oxidative stress response and cellular survival. Circumstantial evidence suggests that activation of p66shc, which acts downstream of tyrosine kinase receptors, may be implicated in Ang II-induced cardiovascular alterations [16]. We therefore attempted to ascertain the Ang II receptor subtype is involved in p66shc activation in isolated rat VSMCs. As shown in Fig. 3, Ang II (100 nM) treatment led to increased phosphorylation of p66shc on serine 36, which was inhibited by the AT1R inhibitor, valsartan, but not by the AT2R inhibitor, PD123319. These data suggest that Ang II increases p66shc activation via AT1R in VSMCs.

**TSA inhibited Ang II-induced p66shc phosphorylation**

Next, we investigated the effect of TSA on Ang II-induced p66shc phosphorylation in VSMCs. Cells were pretreated with TSA (1~10 μM) for 15 min before Ang II (100 nM) was added for 30 min. As shown in Fig. 4, TSA (10 μM) significantly inhibited Ang II-induced p66shc phosphorylation in VSMCs. Finally, we proceeded to investigate whether TSA inhibited Ang II-induced p66shc activation in HEK293T cells ectopically expressing AT1R or AT2R. After transient transfection of HEK293T cells with EGFP-tagged AT1R and AT2R cDNA, the cellular localization of both proteins was observed via fluorescence microscopy (Fig. 5A). Both AT1R and AT2R were primarily localized on the plasma membrane as evidenced by a yellow-orange staining of the membrane due to overlap of green fluorescence (EGFP-tag) and red fluorescence (CellMask deep Red staining). Representative images showing EGFP-tagged AT1R or AT2R, CellMask deep Red, and DAPI staining in Ang II-treated HEK 293T cells are shown in Fig. 5A. In AT1R expressing cells, Ang II treatment resulted in the phosphorylation of p66shc, which was significantly inhibited by TSA (Fig. 5B). Interestingly, neither Ang II-mediated p66shc phosphorylation, nor its inactivation after TSA treatment, was observed in AT2R expressing cells (data not shown).
Fig. 2. Trichostatin A (TSA) inhibited angiotensin II (Ang II)-induced vasoconstriction in rat aorta. Vasoconstriction was evoked by Ang II treatment at doses between 1 and 100 nM in aortic rings with intact (A) or rubbed endothelium (B). Contraction was expressed as a percentage of the pre-contracted tension obtained with a high K+ (60 mM) solution. Each bar represents the mean±S.E.M. (n=6). Control: DMSO vehicle. *p < 0.05 (vs. control), **p < 0.01 (vs. control).

Fig. 3. Angiotensin II evoked p66shc phosphorylation in vascular smooth muscle cells. Cells were treated first with DMSO (control) or the indicated concentrations of valsartan (angiotensin II receptor type 1 inhibitor) (A), or PD123319 (angiotensin II receptor type 2 inhibitor) (B) for 30 min, and subsequently with 100 nM Ang II. Cell lysates were immunoblotted for phospho-p66shc, Shc, and actin. Densitometric scanning was performed to quantify the phospho-p66shc/p66shc levels. Bars represent the mean±S.E.M. (n=4). **p < 0.01 (vs. control), #p < 0.01 (vs. only angiotensin II-treated cells).

These results indicate that p66shc activation in Ang II-mediated signal transduction occurs only through AT1R and is inhibited by TSA.

DISCUSSION

Our study demonstrates that the HDAC inhibitor, TSA, modulates high blood pressure via inhibition of AT1R-mediated p66shc phosphorylation or of ROS production in vascular smooth muscle cells. HDACs mediate the expression of various genes by regulating the proteins involved in chromatin modulation. HDAC inhibition induces the epigenetic modification of genes such as histone acetylation and its intracellular acetylation regulates the ability of histones to bind to DNA. In addition, the acetylation of lysine residues of several other proteins influences its activity as an analogous mechanism, in which non-histone proteins are acted on by acetylases and deacetylases. HDACs are found to interact with a variety of non-histone proteins. There is growing evidence that HDAC inhibitors have potential therapeutic applications in various diseases such as cancer [17], immunological [18] or inflammatory diseases [19]. HDAC inhibitors also exert anti-hypertrophic effects in the heart [20]. TSA was the first natural hydroxamate found to inhibit HDACs [21]. In previous reports, TSA prevented the proliferation of VSMCs and neointimal hyperplasia induced by balloon injury in rat carotid arteries [22]. HDAC inhibition promoted mineralocorticoid receptor acetylation, leading to a decreased transcriptional activity of the mineralocorticoid receptor [23]. In the present study, chronic TSA treatment inhibited aortic coarctation hypertension in an animal model previously used to study the activation of the renin-angiotensin system after low renal perfusion pressure [24]. Recently, Li et al. reported that Ang II up-regulated prorenin receptor expression in cultured cells and hypertensive rats [25]. This result suggests that inhibition of the Ang II signaling via HDAC inhibition might inhibit renin receptor expression, resulting in anti-hypertensive effects. However, some reports indicate that HDAC inhibition increased renin expression in cultured renal cells [26] and renal mesenchymal cells [27]. The mechanisms underlying the anti-hypertensive effects of TSA are complex and not completely elucidated. Epigenetic regulation of Ang II and/or RAS-induced gene expression levels by HDAC inhibition requires further investigation. However, our data suggest that TSA influences the activation of the renin-angiotensin system.

TSA inhibited Ang II-induced vasoconstriction in rat aortas, suggesting that TSA has a vasorelaxing activity.
TSA Inhibits Ang II-induced p66shc Activation

Interestingly, TSA also inhibited Ang II-induced vasoconstriction in aortic rings with rubbed endothelium. This suggested that TSA mainly affects Ang II-induced signaling in VSMCs. TSA inhibited the signal transduction of Ang II and its receptor. Another possibility is that TSA increased intracellular acetylation, indirectly leading to vasorelaxation. It was recently shown that intracellular acetylation upon HDAC inhibition leads to increased cGMP levels in rat VSMCs and rat aortas [28]. This report showed an increase in global lysine acetylation of smooth muscle cell proteins, including those involved in the process of arterial wall contraction and relaxation. p300/CBP-associated factor (PCAF), also known as lysine acetyltransferase, is involved in the acetylation of a number of histone and non-histone proteins. PCAF increases myosin light chain and smooth muscle actin acetylation above the basal level, reducing actomyosin formation and resulting in reduced contractility [28]. Therefore, the anti-hypertensive or vasorelaxing effect of HDAC inhibitor might result in intracellular acetylation of proteins involved in Ang II signaling and may play a role in lowering blood pressure in aortic coarctation rats.

Adaptor protein p66shc is expressed in most mammalian tissues. p66shc−/− mice exhibit an increased resistance to oxidative stress and have a prolonged lifespan [3]. Previous reports show that Ang II induces p66shc upregulation in endothelial cells [8,11]. Genetic deletion of the p66shc adaptor protein protects from Ang II-induced myocardial damage [16]. HDAC inhibition reduced the production of ROS in cardiomyoblasts exposed to hypoxia/reoxygenation [29]. Recently, it was also shown that the intracellular increase of ROS levels following exposure to hydrogen peroxide was suppressed by TSA [30].

The main actions of Ang II are mediated via AT1R and AT2R. In isolated VSMCs, Ang II increased p66shc phosphorylation, which was inhibited by valsartan, a selective AT1R antagonist. These findings suggest that the AT1R signaling pathway mediates Ang II-induced p66shc activation. Our data also indicate that TSA inhibits Ang II-induced p66shc phosphorylation in VSMCs and in AT1R-expressing HEK293T cells. These data suggest that TSA inhibited AT1R-mediated p66shc activation, which is correlated to ROS production. Therefore, the inhibitory activity of TSA on Ang II-induced oxidative stress could contribute to vasorelaxation or to a decreased hypertension.
CONFLICT OF INTEREST
No potential conflict of interest was disclosed.

ACKNOWLEDGEMENTS
This research was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF), which is funded by the Ministry of Education (NRF-2014R1A6A1029617, 2007-0054932) and by the re-

REFERENCES
1. Nagy L, Kao HY, Chaukavarti D, Lin BJ, Haseog CA, Ayer DE, Schreiber SL, Evans RM. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell. 1997;89:373-380.
2. Usui T, Okada M, Mizuno W, Oda M, Ide N, Morita T, Hara Y, Yamawaki H. HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats. Am J Physiol Heart Circ Physiol. 2012;302:H1894-1904.
3. Migliazzo E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci FG. The p66shc adaptor protein controls both stress response and life span in mammals. Nature. 1999;402:309-313.
4. Pellegrini M, Baldari CT. Apoptosis and oxidative stress-related diseases: the p66Shc connection. Curr Mol Med. 2009; 9:392-398.
5. Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66Shc-dependent signaling pathway. Science. 2002; 295:2450-2452.
6. Wu Z, Rogers B, Kachi S, Hackett SF, Sick A, Campochiaro PA. Reduction of p66Shc suppresses oxidative damage in retinal pigmented epithelial cells and retina. J Cell Physiol. 2006;209:996-1005.
7. Sun L, Xiao L, Nie J, Liu FY, Ling GH, Zhu XJ, Tang WB, Chen W, Xia YC, Zhan M, Ma MM, Peng YM, Liu H, Liu YH, Kanwar YS. p66Shc mediates high-glucose and angiotensin II-induced oxidative stress renal tubular injury via mitochondrial-dependent apoptotic pathway. Am J Physiol Renal Physiol. 2010;299:F1014-1025.
8. Kim CS, Jung SB, Naqvi A, Hoffman TA, DeRicco J, Yamamori YM, Kim HS, Lee SK, Park SH, Irani K, Kim B. Reduction of p66Shc suppresses oxidative damage in renal proximal tubular epithelial cells. Korean J Physiol Pharmacol. 2015;19:229-234.
9. Parker FB Jr, Streeter DH, Farrell B, Blackman MS, Sondheimer HM, Anderson GH Jr. Preoperative and postoperative renin levels in coarctation of the aorta. Circulation. 1982;65:513-514.
10. Lee SK, Kim HS, Song YJ, Joo HK, Lee JY, Lee KH, Cho Ed, Cho CH, Park JB, Jeon BH. Alteration of p66shc is associated with endothelial dysfunction in the abdominal aortic coarctation of rats. FEBS Lett. 2008;582:2561-2566.
11. Lee HM, Jeon BH, Won KJ, Lee CK, Park TK, Choi WS, Bae YM, Kim HS, Lee SK, Park SH, Inani K, Kim B. Gene transfer of redox factor-1 inhibits neointimal formation: involvement of platelet-derived growth factor-beta receptor signaling via the inhibition of the reactive oxygen species-mediated Syk pathway. Circ Res. 2009;104:219-227, S5 following S27.
12. Lee SK, Chung JI, Park MS, Joo HK, Lee Ed, Cho Ed, Park JB, Ryoo S, Inani K, Jeon BH. Apurinic/apyrimidinic endonuclease 1 inhibits protein kinase C-mediated p66shc phosphorylation and vasconstriction. Cardiovasc Res. 2011;91:502-509.
13. Jeong HD, Kim HD, Jeong JH. The inhibitory effect of eupatilin on the agonist-induced regulation of vascular contractility. Korean J Physiol Pharmacol. 2013;17:31-36.
14. Lee SK, Lee JY, Joo HK, Cho Ed, Kim CS, Lee SD, Park JB, Jeon BH. Tat-mediated p66shc transcription decreased phosphorylation of endothelial nitric oxide synthase in endothelial cells. Korean J Physiol Pharmacol. 2012;16:199-204.
15. Gniai G, Lagrasta C, Migliazzo E, Spillmann F, Meloni M, Madeppa P, Quaini F, Padura IM, Lanfrancone L, Pelicci P, Emanueli C. Genetic deletion of the p66Shc adaptor protein protects from angiotensin II-induced myocardial damage. Hypertension. 2005;46:433-440.
16. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5:769-784.
17. Bregdon JJ, Xu Y, Szabo SI, An S, Buxton F, Cohen D, Huang Q. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 2007;109:1123-1130.
18. Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol. 2007;150:829-831.
19. Davis FD, Pillai JB, Gupta M, Gupta MP. Concurrent opposite effects of trichostatin A, an inhibitor of histone deacetylases, on expression of alpha-MHC and cardiac tubulins: implication for gain in cardiac muscle contractility. Am J Physiol Heart Circ Physiol. 2005;288:H1477-1490.
20. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1999;274:17174-17179.